American Journal of Cancer Prevention
ISSN (Print): 2328-7314 ISSN (Online): 2328-7322 Website: http://www.sciepub.com/journal/ajcp Editor-in-chief: Nabil Abdel-Hamid
Open Access
Journal Browser
Go
American Journal of Cancer Prevention. 2014, 2(2), 31-36
DOI: 10.12691/ajcp-2-2-3
Open AccessArticle

Dutasteride and Prostate Cancer Risk: Does Family History of Prostate and/or Breast Cancers Influence the Number Needed to Treat? Results from REDUCE

Jean-Alfred Thomas II1, 2, Leah Gerber1, 2, Robert J. Hamilton3, Adriana C. Vidal2, 4, Daniel M. Moreira5, Gerald L. Andriole6 and Stephen J. Freedland1, 7,

1Surgery Section, Durham VA Medical Center, Durham, NC

2Duke Prostate Center, Division of Urological Surgery, Department of Surgery, Duke, University School of Medicine, Durham, NC

3Division of Urology, Department of Surgery, Memorial Sloan Kettering Cancer Institute

4Department of Obstetrics and Gynecology, Duke University School of Medicine, Durham, NC

5The Arthur Smith Institute for Urology, North Shore Long Island Jewish Health System, New Hyde Park, NY

6Washington University School of Medicine in St. Louis, St. Louis, Missouri

7Duke Prostate Center, Division of Urological Surgery, Department of Surgery, Duke, University School of Medicine, Durham, NC;Department of Pathology, Duke University School of Medicine, Durham, NC

Pub. Date: November 26, 2014

Cite this paper:
Jean-Alfred Thomas II, Leah Gerber, Robert J. Hamilton, Adriana C. Vidal, Daniel M. Moreira, Gerald L. Andriole and Stephen J. Freedland. Dutasteride and Prostate Cancer Risk: Does Family History of Prostate and/or Breast Cancers Influence the Number Needed to Treat? Results from REDUCE. American Journal of Cancer Prevention. 2014; 2(2):31-36. doi: 10.12691/ajcp-2-2-3

Abstract

Purpose: In REDUCE, dutasteride was associated with a ~5% absolute reduction in the risk of biopsy-detected prostate cancer (PCa). Material and methods: We tested the influence of family history on the association between dutasteride and PCa diagnosis and calculated the number needed to treat (NNT) with dutasteride to avoid one PCa diagnosis. The REDUCE trial tested dutasteride 0.5mg/day for PCa risk reduction in men aged 50-75 with a serum PSA of 2.5-10.0ng/mL and a negative biopsy. Among men who underwent >1 on-study biopsy with complete data (n=6,415; 78.1%), the association between dutasteride and PCa risk as a function of PCa and/or breast cancer (BCa) family history was examined using multivariable logistic regression. Absolute risk reduction (ARR) and NNT were calculated. Results: On multivariate analysis, dutasteride was significantly associated with lower PCa risk in men without family history (25% lower; p<0.001), PCa family history only (37% lower; p=0.009), or BCa family history only (38% lower; p=0.04). While dutasteride lowered PCa risk in men with both PCa and BCa family history by 15%, this was not significant (p=0.69), though the number of men was small (n=115). ARRs were 6-9% for men with a PCa and/or BCa family history vs. 5% in men with no family history which translated into NNTs of 11-16 in men with PCa and/or BCa family history vs. 21 for men without family history. Conclusion: Using dutasteride as a model of chemoprevention, therapies targeting individuals with specific family histories may improve the risk-benefit profile. However, future studies are warranted to confirm our findings.

Keywords:
prostate cancer family history dutasteride

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]  Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2009; 301: 39-51.
 
[2]  Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003; 349: 215-24.
 
[3]  Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010; 362: 1192-202.
 
[4]  Svatek RS, Lotan Y. Cost utility of prostate cancer chemoprevention with dutasteride in men with an elevated prostate specific antigen. Cancer Prev Res (Phila). 2011; 4: 277-83.
 
[5]  Theoret MR, Ning YM, Zhang JJ, Justice R, Keegan P, Pazdur R. The risks and benefits of 5alpha- reductase inhibitors for prostate-cancer prevention. N Engl J Med. 2011; 365: 97-9.
 
[6]  Hamilton RJ, Kahwati LC, Kinsinger LS. Knowledge and use of finasteride for the prevention of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2010; 19: 2164-71.
 
[7]  Svatek RS, Lee JJ, Roehrborn CG, Lippman SM, Lotan Y. The cost of prostate cancer chemoprevention: a decision analysis model. Cancer Epidemiol Biomarkers Prev. 2006; 15: 1485-9.
 
[8]  Johns LE, Houlston RS. A systematic review and meta-analysis of familial prostate cancer risk. BJU Int. 2003; 91: 789-94.
 
[9]  Cerhan JR, Parker AS, Putnam SD, Chiu BC, Lynch CF, Cohen MB, et al. Family history and prostate cancer risk in a population-based cohort of Iowa men. Cancer Epidemiol Biomarkers Prev. 1999; 8: 53-60.
 
[10]  Liede A, Karlan BY, Narod SA. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2004; 22: 735-42.
 
[11]  Madersbacher S, Alcaraz A, Emberton M, Hammerer P, Ponholzer A, Schroder FH, et al. The influence of family history on prostate cancer risk: implications for clinical management. BJU international. 2011; 107: 716-21.
 
[12]  Thomas JA, 2nd, Gerber L, Moreira DM, Hamilton RJ, Banez LL, Castro-Santamaria R, et al. Prostate cancer risk in men with prostate and breast cancer family history: results from the REDUCE study (R1). Journal of internal medicine. 2011.
 
[13]  Vollmer RT, Montana GS. Predicting tumor failure in prostate carcinoma after definitive radiation therapy: limitations of models based on prostate-specific antigen, clinical stage, and Gleason score. Clin Cancer Res. 1999; 5: 2476-84.
 
[14]  Freedland SJ, Jalkut M, Dorey F, Sutter ME, Aronson WJ. Race is not an independent predictor of biochemical recurrence after radical prostatectomy in an equal access medical center. Urology. 2000; 56: 87-91.
 
[15]  Wilt TJ, Macdonald R, Hagerty K, Schellhammer P, Tacklind J, Somerfield MR, et al. 5-alpha- Reductase inhibitors for prostate cancer chemoprevention: an updated Cochrane systematic review. BJU international. 2010; 106: 1444-51.
 
[16]  Reed SD, Scales CD, Jr., Stewart SB, Sun J, Moul JW, Schulman KA, et al. Effects of family history and genetic polymorphism on the cost-effectiveness of chemoprevention with finasteride for prostate cancer. J Urol. 2011; 185: 841-7.
 
[17]  Ridker PM, MacFadyen JG, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, et al. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER). Circ Cardiovasc Qual Outcomes. 2009; 2: 616-23.
 
[18]  Theoret MR, Ning YM, Zhang JJ, Justice R, Keegan P, Pazdur R. The risks and benefits of 5alpha- reductase inhibitors for prostate-cancer prevention. The New England journal of medicine. 2011; 365: 97-9.